Ballentine Partners LLC Takes Position in QIAGEN N.V. $QGEN

Ballentine Partners LLC purchased a new position in shares of QIAGEN N.V. (NYSE:QGEN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 5,001 shares of the company’s stock, valued at approximately $240,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Voya Investment Management LLC boosted its position in QIAGEN by 52.3% during the 1st quarter. Voya Investment Management LLC now owns 245,657 shares of the company’s stock worth $9,845,000 after purchasing an additional 84,332 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in QIAGEN during the 4th quarter worth $202,000. GAMMA Investing LLC boosted its position in QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after purchasing an additional 1,425 shares during the period. Cetera Investment Advisers boosted its position in QIAGEN by 23.2% during the 1st quarter. Cetera Investment Advisers now owns 13,917 shares of the company’s stock worth $551,000 after purchasing an additional 2,620 shares during the period. Finally, AQR Capital Management LLC boosted its position in QIAGEN by 69.4% during the 1st quarter. AQR Capital Management LLC now owns 178,425 shares of the company’s stock worth $7,164,000 after purchasing an additional 73,122 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

QIAGEN Price Performance

NYSE QGEN opened at $43.88 on Tuesday. The stock has a market capitalization of $9.75 billion, a P/E ratio of 25.93, a P/E/G ratio of 2.32 and a beta of 0.64. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The business’s fifty day moving average is $47.82 and its two-hundred day moving average is $45.14. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61.

QIAGEN (NYSE:QGEN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. During the same quarter in the prior year, the company earned $0.55 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts forecast that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on QGEN. Bank of America upped their price target on shares of QIAGEN from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, June 26th. Barclays assumed coverage on shares of QIAGEN in a report on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 price objective on the stock. Wall Street Zen lowered shares of QIAGEN from a “strong-buy” rating to a “buy” rating in a report on Monday, August 11th. UBS Group upped their target price on shares of QIAGEN from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Finally, Cowen reiterated a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.